If they perform, they are able to volunteer for the A4 study. About one-third of these tested will take part in the scholarly study at 60 hospitals and clinics nationwide. Although there have been a few drugs that showed promise for the A4 study, solanezumab was selected for at least two factors. ‘It has a good basic safety profile, which really is a big offer when giving a drug to normal people clinically,’ stated Sperling, who was quoted on Alzforum, a web-based forum of researchers trying to understand Alzheimer’s.Consistent with previous guidance, the business anticipates completing individual enrolment and randomization for ANCHOR in 2011 and reporting top-line outcomes from the ANCHOR trial in 2011. This trial is made to evaluate the safety and efficacy of 2 grams and 4 grams of AMR101 in patients with high triglyceride amounts who are also on statin therapy for elevated LDL cholesterol amounts. No prescription omega-3 centered drug, such as AMR101, is normally approved in the U currently.S. Because of this indication. Dr. Declan Doogan, Amarin’s Interim CEO, stated: ‘We are really delighted that the MARINE research has had the opportunity to complete recruitment quicker than we primarily expected and we very much anticipate reviewing and reporting the outcomes of this trial early in 2011.’ He added, ‘Elevated triglyceride levels are more and more being known and treated as an unbiased modifiable risk element for cardiovascular disease in much the same way as elevated LDL cholesterol levels were greater than a 10 years ago.